

Supplementary table 1. Baseline characteristics, first and second eyes.							
		Year completer					
	Baseline	1	2	3	5	7	10
First eyes	3 008	1 964	1 219	797	349	158	33
Age							
-Median	80	79	79	78	77	77	77
-IQR	74–85	74–84	73–83	73–83	73–82	73–82	73–81
-Range	50–101	52–101	52–97	54–97	54–93	56–92	60–92
Females	2 032	1 342	822	543	240	111	23
-%	68	68	67	68	69	70	70
Baseline VA, mean	54	58	60	60	62	61	60
-SD	21	17	16	16	14	16	14
Eyes with VA ≤35 ETDRS letters *, n	381	121	57	35	9	6	1
-%	13	6	5	4	3	4	8
Eyes with VA ≥70 ETDRS letters **, n	514	391	256	181	84	41	7
-%	17	20	21	23	24	26	21
Second eyes	836	589	396	258	120	36	10
Age							
-Median	81	80	79	79	79	77	77
-IQR	76–85	76–84	75–84	75–83	74–83	75–80	75–79
-Range	54–96	54–96	54–95	54–93	54–90	65–86	75–85
Females	607	442	299	189	93	31	10
-%	73	75	76	73	78	86	100
Baseline VA, mean	59	63	65	66	66	67	63
-SD	19	15	14	14	13	14	20
Eyes with VA ≤35 ETDRS letters *, n	71	21	9	5	2	1	1
-%	9	4	2	2	2	3	3
Eyes with VA ≥70 ETDRS letters **, n	230	182	147	100	49	15	5
-%	28	31	37	39	41	42	50

IQR, interquartile range; VA, visual acuity; SD, standard deviation; *Snellen equivalent ≤20/200 Snellen; **Snellen equivalent ≥ 20/40 Snellen.

Supplementary table 2. Mean change of VA and proportion of eyes continuing follow-up from baseline.

Year completers																										
	n	Base line VA	n	%	Base line VA	Change in VA	n	%	Base line VA	Change in VA	n	%	Base line VA	Change in VA	n	%	Base line VA	Change in VA	n	%	Base line VA	Change in VA	n	%	Base line VA	Change in VA
All eyes	3 780	55	2 553		59	+2	1 615		61	+2	1055		62	0	470		63	-2	194		62	-2	43		61	-4
1st eye	2 967	54	1 964		58	+3	1 219		60	+2	797		60	0	349		62	-2	158		61	0	33		60	-2
2nd eye	813	59	589		63	0	396		65	-1	258		66	-2	121		66	-2	36		67	-10	10		63	-12
Baseline VA ETDRS letters																										
<35	452	12	142	31	14	+25	66	15	13	+32	40	9	12	+31	11	2	11	+42	7	2	13	+43	2	0.4	20	+25
35-<60	1 265	46	817	65	47	+6	487	38	48	+8	302	27	48	+7	123	10	50	+7	57	5	48	+11	14	1	47	+12
60-<70	1 319	65	1 021	77	65	0	659	50	66	-1	432	33	66	-3	203	15	66	-3	74	6	66	-5	15	1	66	-4
≥70	744	77	573	77	77	-4	403	54	77	-7	281	38	77	-9	133	18	77	-12	56	8	77	-16	12	2	76	-28
All eyes stratified by treatment starting year																										
2008	155	51	118	76	53	+2	71	46	55	+2	48	31	56	-1	29	19	59	-4	14	9	59	-6	6	4	62	-10
2009	176	51	114	65	56	+1	76	43	57	+1	60	34	56	-1	36	20	62	-1	21	12	63	-1	15	9	64	-9
2010	204	54	159	78	55	+1	112	55	57	+2	88	43	59	-1	55	27	60	-2	41	20	59	1	22	11	58	0
2011	224	52	162	72	55	+2	113	50	58	+2	78	35	61	-1	49	22	62	-4	32	14	62	-4	-	-	-	-
2012	288	54	227	79	58	+1	154	53	61	+2	114	40	61	0	73	25	63	-1	38	13	63	-1	-	-	-	-
2013	336	56	238	71	60	+2	169	50	62	+2	118	35	63	-1	68	20	65	0	38	11	65	-3	-	-	-	-
2014	373	56	266	71	60	+2	178	48	61	+1	138	37	62	-1	79	21	65	-1	-	-	-	-	-	-	-	-
2015	311	57	228	73	61	+3	162	52	63	0	137	44	63	-1	81	26	65	-5	-	-	-	-	-	-	-	-
2016	377	56	267	71	62	+1	192	51	63	+2	152	40	64	2	-	-	-	-	-	-	-	-	-	-	-	-
2017	301	55	234	78	60	+3	180	60	61	+3	122	41	62	-1	-	-	-	-	-	-	-	-	-	-	-	-
2018	380	56	288	76	62	+2	208	55	63	+1	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2019	343	54	252	73	58	+5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2020	312	55	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

VA, visual acuity; ETDRS, Early treatment diabetic retinopathy study

Supplementary table 3. Median number of annual and mean cumulative intravitreal anti-VEGF injections stratified by the year of treatment initiation and baseline visual acuity.												
	Year completers											
	1		2		3		5		7		10	
	MD	IQR	MD	IQR	MD	IQR	MD	IQR	MD	IQR	MD	IQR
1st eye	6	5–8	6	3–7	6	3–7	6	4–7	6	3.75–7	6	1.5–8
2nd eye	6	4–8	5	3–7	6	3–7	6	2.75–7	5	3–6	5	1.5–7
Cumulative IVI count*	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
1st eye	6.2	2.1	12	4.0	17	5.7	29	8.5	39	12	51	18
2nd eye	5.9	2.1	11	4.3	17	5.9	27	10	38	13	62	11
Treatment starting year												
	MD	IQR	MD	IQR	MD	IQR	MD	IQR	MD	IQR	MD	IQR
2008	5	3–6	4	2–6	4	2–6	7	5–8	6	2–7	4	0–8
2009	6	5–6	5	3–6	5	2–6	7	3–9	4	3–6	6	3–7
2010	6	5–6	5	3–6	7	4–9	7	5–8	6	4–7	5	0–8
2011	6	5–6	6	3–8	7	5–9	6	4–7	5	3–6	–	–
2012	6.5	6–8	7	4–9	6	5–7	6	4–7	6	4–7	–	–
2013	7	6–9	5	3–7	6	3–7	5	3–7	5.5	3–7	–	–
2014	6	5–8	6	3–7	5	3–6	6	3–7	–	–	–	–
2015	6	5–8	6	3–7	5	4–7	6	4–7	–	–	–	–
2016	6	4–7	6	2–7	6	3–7	–	–	–	–	–	–
2017	7	5–9	5	3–7	6	4–8	–	–	–	–	–	–
2018	7	5–8	6	3–8	–	–	–	–	–	–	–	–
2019	7	5–9	–	–	–	–	–	–	–	–	–	–
2020	–	–	–	–	–	–	–	–	–	–	–	–
Baseline VA												
<35	6	4–7	5	3–7	5	3–7	6	4–8	6	4–7	1**	–
35–<60	6	5–8	6	4–7	6	4–7	6	3–8	5	3–7	5.5	3–8
60–<70	6	5–8	6	3–7	6	4–7	6	4–7	6	3–7	5	0–7
≥70	6	4–7	5	3–7	6	3–7	6	3–7	5	4–6	6	4–8

*At end of each year; **n= 2 eyes. MD, median; IQR, interquartile range; SD, standard deviation; IVI, intravitreal injection

Supplementary table 4. Median number of annual and mean cumulative number of non-injection visits stratified by the year of treatment initiation and baseline visual acuity.												
	Year completers											
	1		2		3		5		7		10	
	MD	IQR	MD	IQR	MD	IQR	MD	IQR	MD	IQR	MD	IQR
1st eye	4	3–4	3	2–4	3	2–4	3	2–4	3	2–4	3	2–4
2nd eye	4	3–5	3	2–4	3	2–4	3	2–4	4	3–5	2	2–4
Cumulative visit count*	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
1st eye	3.7	1.2	6.9	1.9	9.9	2.6	16	3.8	22	4.9	29	6.0
2nd eye	3.9	1.2	7.1	2.0	10	2.6	17	4.2	22	4.5	29	4.3
Treatment starting year												
	MD	IQR	MD	IQR	MD	IQR	MD	IQR	MD	IQR	MD	IQR
2008	3	3–4	3	2–3	2	2–3	3	2–4	3.5	2–4	3	1–3
2009	3	2–3	2	2–3	2	2–2	3	2–4	4	3–4	4	2–5
2010	3	2–3	2	2–2	3	2–3	3	2–4	3	3–5	2	1–4
2011	3	2–3	3	2–4	3	2–4	3	3–4	3.5	2–4	–	–
2012	4	3–4	3	3–4	3	2–4	3	2–4	3	2–4	–	–
2013	4	3–5	3	2–4	3	3–4	3	2–4	3	2–5	–	–
2014	4	3–4	3	3–4	3	2–4	4	2–5	–	–	–	–
2015	4	3–5	4	3–4	3	2–4	3	2–4	–	–	–	–
2016	4	3–5	3	2–4	4	3–4	–	–	–	–	–	–
2017	4	3–5	4	3–5	3	2–4	–	–	–	–	–	–
2018	4	3–5	4	2–5	–	–	–	–	–	–	–	–
2019	4	3–5	–	–	–	–	–	–	–	–	–	–
2020	–	–	–	–	–	–	–	–	–	–	–	–
Baseline VA												
<35	3	3–4	3	2–3	3	2–4	3	2–4	3	1–4	2**	2–2
35–<60	3	3–4	3	2–4	3	2–4	3	2–4	3	2–4	3	2–5
60–<70	4	3–4	3	2–4	3	2–4	3	2–4	3	2–4	3	2–4
≥70	4	3–5	3	2–4	3	2–4	3	2–4	4	3–4	2.5	1–4

*At end of each year; **n= 2 eyes. MD, median; IQR, interquartile range; SD, standard deviation

Supplementary table 5. Eyes lost to follow-up stratified by cause.												
	Endpoint at year											
	1		2		3		5		7		10	
Eyes initiated treatment. n	3 523		3 170		2 781		2 084		1 389		535	
	N	%	N	%	N	%	N	%	N	%	N	%
Eyes continued treatment	2 618	74	1 691	53	1110	40	495	24	200	14	44	8.2
Lost to follow-up	905	26	1 479	47	1671	60	1 589	76	1 189	86	491	92
Inactivation of disease	165	18	383	26	447	27	416	26	294	25	125	26
Poor treatment result	503	56	702	48	748	45	697	44	521	44	215	44
Poor general health	59	6.5	120	8.1	156	9.3	157	9.9	120	10	53	11
Death*	25	2.8	35	2.4	51	3.1	54	3.4	50	4.2	14	2.9
Patient declined treatment	78	8.6	111	7.5	119	7.1	117	7.4	89	7.5	39	7.9
Other or unknown	75	8.3	128	8.7	150	9.0	148	9.3	115	9.7	45	9.2

*Death within 1 month from last visit

Supplementary table 6. Median days from Last Observation Carried Forward (LOCF) visit to end of index year and percentage of visits within 1-3 months before end of index year.							
Index year	n (eyes)	Days to end of index year from LOCF visit (median)	Interquartile range		% of LOCF visits within 1 month of end of index year	% of LOCF visits within 2 months of end of index year	% of LOCF visits within 3 months of end of index year
			25 percentile	75 percentile			
1	1 964	61	27	105	28	49	66
2	1 219	60	29	113	26	51	66
3	797	66	31	117	24	48	63
5	349	63	30	114	25	45	64
7	158	62	24	103	30	48	68
10	33	93	36	158	17	34	46